SCHEMBL20600762

SCHEMBL20600762

Nc1nc(-c2ccc3ncsc3c2)c(-c2ccc3ncsc3c2)n2ccnc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.50
TGFBR1 P36897 9/20 0.47
KDM1A O60341 2/20 0.43
GRIA1 P42261 2/20 0.40
RIPK1 Q13546 1/20 0.40
BMPR1A P36894 1/20 0.39
SMAD2 Q15796 1/20 0.39
VRK1 Q99986 1/20 0.39
PDE4B Q07343 1/20 0.38
PDE4D Q08499 1/20 0.38
APP P05067 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
ADORA1 P30542 1/20 0.38
CCNT1 O60563 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CSNK1E P49674 1/20 0.37
CDK9 P50750 1/20 0.37
CDK5 Q00535 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20600615 0.93 GRIA1 (0.50) DYRK1ATGFBR1KDM1AGRIA1ADORA2A
SCHEMBL20600512 0.90 TGFBR1 (0.45) DYRK1ATGFBR1KDM1AGRIA1RIPK1
SCHEMBL20600542 0.89 ADORA2A (0.48) DYRK1ATGFBR1KDM1AADORA2AADORA2B
SCHEMBL20600784 0.84 TGFBR1 (0.42) DYRK1ATGFBR1KDM1AGRIA1RIPK1
SCHEMBL20600570 0.81 KDM1A (0.45) TGFBR1KDM1AGRIA1ADORA2ACCNT1
SCHEMBL20600493 0.78 GRIA1 (0.46) DYRK1AGRIA1ADORA2ACCNT1CCNA2
SCHEMBL20600540 0.76 PI4KA (0.46) GRIA1
SCHEMBL20600785 0.76 GRIA1 (0.45) GRIA1ADORA2ACCNT1CCNA2CDK2
SCHEMBL20600619 0.74 SRC (0.46) DYRK1AGRIA1ADORA2AADORA1CSNK1E
SCHEMBL25205395 0.73 ADORA2A (0.47) DYRK1ATGFBR1GRIA1BMPR1ASMAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US claimed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP claimed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO claimed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 DYRK1A 1125/4885TGFBR1 1069/4885KDM1A 3582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.